drugset / Trial / NCT07018492
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Timeline
- Start
- 2025-08-30
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zatolmilast | Small molecule | — | Oral |
Indications
No indication recorded.